Mutation signatures of carcinogen exposure: Genome-wide detection and new opportunities for cancer prevention

Genome Medicine

Volumn 6, Issue 3, 2014, Pages

  Poon, Song L ^a,b   McPherson, John R ^b   Tan, Patrick ^b,c,d,e   Teh, Bin T ^a,b   Rozen, Steven G ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ARISTOLOCHIC ACID; AROMATIC HYDROCARBON; BENZENE; CARCINOGEN; COAL TAR; DNA; DNA DIRECTED DNA POLYMERASE EPSILON; ENVIRONMENTAL MUTAGEN; MUTAGENIC AGENT; NITROSAMINE; POLYCYCLIC AROMATIC HYDROCARBON; TEMOZOLOMIDE; TOBACCO SMOKE;

CANCER PREVENTION; CARCINOGENICITY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MUTAGENESIS; EXPOSURE; FOOD CONTAMINATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOME; HEPATITIS B VIRUS; HUMAN; INDEL MUTATION; LIVER CELL CARCINOMA; MISMATCH REPAIR; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; URINARY TRACT CANCER;

EID: 84899533639     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm541     Document Type: Review

References (87)

1. Pott P. Cancer Scrot. Chirurgical Observations Relative to the Cataract, the Polypus of the Nose, Cancer of the Scrotum, Different Kinds of Ruptures, and the Mortification of the Toes and Feet 1775, London: Hawes, Clarke, Collins.
2. Yamagiwa K, Ichikawa K. Experimental study of the pathogenesis of carcinoma. J Cancer Res 1918, 3:1-21.
3. Cook JW, Hewett CL, Hieger I. The isolation of a cancer-producing hydrocarbon from coal tar. Parts I, II, and II. J Chem So (Resumed) 1933, 395-405.
4. Carrell CJ, Carrell TG, Carrell HL, Prout K, Glusker JP. Benzo[a]pyrene and its analogues: structural studies of molecular strain. Carcinogenesis 1997, 18:415-422. 10.1093/carcin/18.2.415, 9054637.
5. Penning TM. Chemical Carcinogenesis 2011, New York: Humana Press.
6. Ikehata H, Ono T. The mechanisms of UV mutagenesis. J Radiat Res 2011, 52:115-125. 10.1269/jrr.10175, 21436607.
7. Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res 2000, 455:29-60. 10.1016/S0027-5107(00)00064-6, 11113466.
8. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. 10.1038/nature12477, 3776390, 23945592.
9. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, Michielin O, Muehlethaler K, Speiser D, Beckmann JS, Xenarios I, Halazonetis TD, Jongeneel CV, Stevenson BJ, Antonarakis SE. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012, 44:133-139.
10. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, Myint SS, Rajasegaran V, Heng HL, Gan A, Zang ZJ, Wu Y, Wu J, Lee MH, Huang D, Ong P, Chan-on W, Cao Y, Qian CN, Lim KH, Ooi A, Dykema K, Furge K, Kukongviriyapan V, Sripa B, Wongkham C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012, 44:690-693. 10.1038/ng.2273, 22561520.
11. Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 2013, 45:1474-1478. 10.1038/ng.2806, 24185513.
12. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, Chin SY, Tan IB, Ng CC, Yu W, Wu Y, Lee M, Wu J, Poh D, Wan WK, Rha SY, So J, Salto-Tellez M, Yeoh KG, Wong WK, Zhu YJ, Futreal PA, Pang B, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012, 44:570-574. 10.1038/ng.2246, 22484628.
13. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, et al. CORGI Consortium; WGS500 Consortium Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013, 45:136-144. 3785128, 23263490, CORGI Consortium; WGS500 Consortium.
14. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120. 10.1016/j.cell.2012.08.029, 3557932, 22980975.
15. Nagarajan N, Bertrand D, Hillmer AM, Zang ZJ, Yao F, Jacques PE, Teo AS, Cutcutache I, Zhang Z, Lee WH, Sia YY, Gao S, Ariyaratne PN, Ho A, Woo XY, Veeravali L, Ong CK, Deng N, Desai KV, Khor CC, Hibberd ML, Shahab A, Rao J, Wu M, Teh M, Zhu F, Chin SY, Pang B, So JB, Bourque G, et al. Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol 2012, 13:R115. 10.1186/gb-2012-13-12-r115, 23237666.
16. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013, 5:197ra101.
17. Chen CH, Dickman KG, Moriya M, Zavadil J, idorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012, 109:8241-8246. 10.1073/pnas.1119920109, 3361449, 22493262.
18. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, Moriya M, Niknafs N, Douville C, Karchin R, Turesky RJ, Pu YS, Vogelstein B, Papadopoulos N, Grollman AP, Kinzler KW, Rosenquist TA. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med 2013, 5:197ra102.
19. Hollstein M, Moriya M, Grollman AP, Olivier M. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mut Res 2013, 753:41-49.
20. Gokmen MR, Cosyns JP, Arlt VM, Stiborova M, Phillips DH, Schmeiser HH, Simmonds MS, Cook HT, Vanherweghem JL, Nortier JL, Lord GM. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med 2013, 158:469-477. 10.7326/0003-4819-158-6-201303190-00006, 23552405.
21. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012, 485:502-506. 3367798, 22622578.
22. Drobetsky EA, Grosovsky AJ, Glickman BW. The specificity of UV-induced mutations at an endogenous locus in mammalian cells. Proc Natl Acad Sci U S A 1987, 84:9103-9107. 10.1073/pnas.84.24.9103, 299700, 3480533.
23. Besaratinia A, Li H, Yoon JI, Zheng A, Gao H, Tommasi S. A high-throughput next-generation sequencing-based method for detecting the mutational fingerprint of carcinogens. Nucleic Acids Res 2012, 40:e116. 10.1093/nar/gks610, 3424585, 22735701.
24. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies HR, Ordoñez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun YA, McLaughlin SF, Peckham HE, Tsung EF, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190. 10.1038/nature08629, 2880489, 20016488.
25. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451. 10.1038/sj.onc.1205803, 12379884.
26. Phillips DH. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 2002, 23:1979-2004. 10.1093/carcin/23.12.1979, 12507921.
27. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143:e1S-e29S. 10.1378/chest.12-2345, 23649439.
28. Hecht SS. Lung carcinogenesis by tobacco smoke. Int J Cancer 2012, 131:2724-2732. 10.1002/ijc.27816, 3479369, 22945513.
29. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992, 339:943-946. 10.1016/0140-6736(92)91528-G, 1348796.
30. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B: from mutational spectrometry to carcinogenesis. Carcinogenesis 2001, 22:535-545. 10.1093/carcin/22.4.535, 11285186.
31. Bailey EA, Iyer RS, Stone MP, Harris TM, Essigmann JM. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci U S A 1996, 93:1535-1539. 10.1073/pnas.93.4.1535, 39975, 8643667.
32. Shen HM, Ong CN. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 1996, 366:23-44. 10.1016/S0165-1110(96)90005-6, 8921985.
33. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW, Santella RM. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996, 24:38-42.
34. Bannasch P, Khoshkhou NI, Hacker HJ, Radaeva S, Mrozek M, Zillmann U, Kopp-Schneider A, Haberkorn U, Elgas M, Tolle T, et al. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res 1995, 55:3318-3330.
35. Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 2009, 286:22-28. 10.1016/j.canlet.2009.02.053, 19345001.
36. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJ, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343:189-193. 10.1126/science.1239947, 24336570.
37. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009, 15:4622-4629. 10.1158/1078-0432.CCR-08-3012, 2737355, 19584161.
38. Gaskell M, McLuckie KI, Farmer PB. Comparison of the repair of DNA damage induced by the benzene metabolites hydroquinone and p-benzoquinone: a role for hydroquinone in benzene genotoxicity. Carcinogenesis 2005, 26:673-680.
39. Saberi Hosnijeh F, Christopher Y, Peeters P, Romieu I, Xun W, Riboli E, Raaschou-Nielsen O, Tjonneland A, Becker N, Nieters A, Trichopoulou A, Bamia C, Orfanos P, Oddone E, Luján-Barroso L, Dorronsoro M, Navarro C, Barricarte A, Molina-Montes E, Wareham N, Vineis P, Vermeulen R. Occupation and risk of lymphoid and myeloid leukaemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Occup Environ Med 2013, 70:464-470. 10.1136/oemed-2012-101135, 23576671.
40. Vlaanderen J, Lan Q, Kromhout H, Rothman N, Vermeulen R. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med 2012, 55:779-785. 10.1002/ajim.22087, 22729623.
41. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013, 45:977-983. 10.1038/ng.2701, 3902892, 23852168.
42. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013, 494:366-370. 10.1038/nature11881, 3907282, 23389445.
43. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993, 341:387-391. 10.1016/0140-6736(93)92984-2, 8094166.
44. Bhattacharjee P, Bhattacharyya D. Characterization of the aqueous extract of the root of Aristolochia indica: evaluation of its traditional use as an antidote for snake bites. J Ethnopharmacol 2013, 145:220-226. 10.1016/j.jep.2012.10.056, 23174522.
45. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008, 74:158-169. 10.1038/ki.2008.129, 18418355.
46. Heinrich M, Chan J, Wanke S, Neinhuis C, Simmonds MS. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2-a global assessment based on bibliographic sources. J Ethnopharmacol 2009, 125:108-144. 10.1016/j.jep.2009.05.028, 19505558.
47. Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B, Wu L, Truong S, Fernandes A, Grollman AP. TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 2011, 129:1532-1536. 10.1002/ijc.26077, 21413016.
48. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002, 17:265-277. 10.1093/mutage/17.4.265, 12110620.
49. US Department of Health and Human Services The Health Consequences of Smoking - 50 Years of Progress, A Report of the Surgeon General 2014 2014, Rockville, MD: Public Health Service Office of the Surgeon General, US Department of Health and Human Services.
50. Talikka M, Sierro N, Ivanov NV, Chaudhary N, Peck MJ, Hoeng J, Coggins CR, Peitsch MC. Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol 2012, 42:877-889. 10.3109/10408444.2012.725244, 3491444, 22989067.
51. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003, 3:733-744. 10.1038/nrc1190, 14570033.
52. Bedard LL, Massey TE. Aflatoxin B1-induced DNA damage and its repair. Cancer Lett 2006, 241:174-183. 10.1016/j.canlet.2005.11.018, 16458422.
53. Eaton DL, Gallagher EP. Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 1994, 34:135-172. 10.1146/annurev.pa.34.040194.001031, 8042848.
54. Aflatoxin. IARC Monographs 1985, 3-87. .
55. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338:1356-1359. 10.1016/0140-6736(91)92236-U, 1682737.
56. Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 2009, 286:29-37. 10.1016/j.canlet.2009.02.057, 19376640.
57. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000, 6:2585-2597.
58. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 2005, 53:241-252. 10.1016/j.critrevonc.2004.10.004, 15718149.
59. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61. 10.1016/S0305-7372(97)90019-0, 9189180.
60. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005, 65:6394-6400. 10.1158/0008-5472.CAN-05-0715, 16024643.
61. Margison GP, Santibanez Koref MF, Povey AC. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002, 17:483-487. 10.1093/mutage/17.6.483, 12435845.
62. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, D'Atri S. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 2004, 66:478-491.
63. A review of human carcinogens: Chemical agents and related occupations. IACR Monographs 2012, 100F.
64. Cogliano VJ, Baan R, Straif K, IARC Monographs programme staff Updating IARC's carcinogenicity assessment of benzene. Am J Ind Med 2011, 54:165-167. 10.1002/ajim.20916, 21259300, IARC Monographs programme staff.
65. Whysner J, Reddy MV, Ross PM, Mohan M, Lax EA. Genotoxicity of benzene and its metabolites. Mutat Res 2004, 566:99-130. 10.1016/S1383-5742(03)00053-X, 15164977.
66. Nakayama A, Noguchi Y, Mori T, Morisawa S, Yagi T. Comparison of mutagenic potentials and mutation spectra of benzene metabolites using supF shuttle vectors in human cells. Mutagenesis 2004, 19:91-97. 10.1093/mutage/geh009, 14981155.
67. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013, 45:970-976. 10.1038/ng.2702, 3789062, 23852170.
68. Fishel R, Kolodner RD. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev 1995, 5:382-395. 10.1016/0959-437X(95)80055-7, 7549435.
69. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001, 411:390-395. 10.1038/35077256, 11357148.
70. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002, 94:2766-2792. 10.1002/cncr.10593, 12173348.
71. Frank SA. Dynamics of Cancer Incidence, Inheritance, and Evolution 2007, Princeton (NJ): Princeton University Press.
72. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009, 361:1475-1485. 10.1056/NEJMra0804615, 19812404.
73. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW. DNA repair, genome stability, and aging. Cell 2005, 120:497-512. 10.1016/j.cell.2005.01.028, 15734682.
74. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158. 10.1038/nature05610, 2712719, 17344846.
75. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993. 10.1016/j.cell.2012.04.024, 3414841, 22608084.
76. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013, 3:246-259. 10.1016/j.celrep.2012.12.008, 3588146,3588146, 23318258.
77. Moudgil V, Redhu D, Dhanda S, Singh J. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. J Environ Pathol Toxicol Oncol 2013, 32:165-175. 10.1615/JEnvironPatholToxicolOncol.2013007166, 24099430.
78. Micu G, Staniceanu F, Zurac S, Bastian A, Gramada E, Nichita L, Popp C, Sticlaru L, Andrei R, Socoliuc C. Carcinogenesis and infection with Helicobacter pylori. Rom J Intern Med 2010, 48:299-306.
79. Deligeoroglou E, Christopoulos P, Aravantinos L, Papadias K. Human papilloma virus molecular profile and mechanisms of cancerogenesis: a review. Eur J Gynaecol Oncol 2009, 30:128-132.
80. Review of human carcinogens. IARC Monographs 2012, 100.
81. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694. 10.1093/jnci/djn389, 2639291, 19033571.
82. Guan N, Huang X, Lan L, Luo Z, Zhang X. Graph based semi-supervised non-negative matrix factorization for document clustering. 2012 11th International Conference on Machine Learning and Applications (ICMLA), Volume 1 2012, 404-408. Institute of Electrical and Electronics Engineers.
83. Hillebrand M, Krebel U, Wohler C, Kummert F. Traffic sign classifier adaption by semi-supervised co-training. Artificial Neural Networks Pattern Recognition 2012, 193-200.
84. Lefevre A, Bach F, Fevotte C. Semi-supervised NMF with time-frequency annotations for single-channel source separation. ISMIR 2012: 13th International Society for Music Information Retrieval Conference [http://ismir2012.ismir.net/event/papers/115-ismir-2012.pdf].
85. Morikawa Y, Yukawa M. A sparse optimization approach to supervised NMF based on convex analytic method. Proceedings of the 38th IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP): May 2013 2013, 6078-6082. Vancouver, Canada: Institute of Electrical and Electronics Engineers.
86. Chen M, Chen WS, Chen B, Pan B. Non-negative sparse representation based on block NMF for face recognition. Lecture Notes Comput Sci 2013, 8232:26-33.
87. Sindhwani V, Ghoting A. Large-scale distributed non-negative sparse coding and sparse dictionary learning. Proceedings of the 18th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining: August 2012 2012, 489-497. Beijing, China: Association for Computing Machinery.